Diagnostics Start-up Molecular Metabolism Purchases Assets of NextGen Sciences' Dx Business | GenomeWeb

Start-up biotech firm Molecular Metabolism has purchased the assets of NextGen Sciences' diagnostics subsidiary.

Molecular Metabolism plans to use the assets, which include mass spec assays for a number of potential protein biomarkers as well as mass spec instrumentation and research samples, for its diagnostic development efforts, company Founder Patrick Muraca, told ProteoMonitor. He declined to say how much the company paid for the assets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.